Author

John T. Phoenix

Loyola University ChicagoORCID 0000-0001-7954-4059Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Audris BudreikaiD· 3 shared Donald J. Vander GriendiD· 3 shared Marina G. FerrariiD· 3 shared Raymond J. KostlaniD· 3 shared Steven KregeliD· 3 shared Kristen S. YoungiD· 2 shared Pushpinder BawaiD· 2 shared Sean William FanningiD· 2 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Audris BudreikaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 9, 2026

A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation.

Raymond J. Kostlan, John T. Phoenix, Audris Budreika…·Steven Kregel

This study identifies METTL3 as a non-enzymatic AR co-regulator that promotes prostate cancer proliferation by supporting AR-driven transcriptional programs.

DOI 10.64898/2026.07.08.737095

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 18, 2025

SOX2 utilizes FOXA1 as a heteromeric transcriptional partner to drive proliferation in therapy-resistant prostate cancer

John T. Phoenix, Audris Budreika, Devin A. Schmeck…·Steven Kregel

This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.

2 citations

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyMolecular Cancer ResearchPeer-reviewedMay 31, 2024

Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies

Raymond J. Kostlan, John T. Phoenix, Audris Budreika…·Steven Kregel

This paper develops humanized mouse models of metastatic prostate cancer to evaluate therapies, showing improved immune interactions and response to hormonal and immunotherapies.

10 citations

mouseexperimental assay

𝕏 PostBluesky